MedPath

Tramadol

Generic Name
Tramadol
Brand Names
Conzip, Durela, Qdolo, Ralivia, Ryzolt, Seglentis, Tridural, Ultracet, Ultram, Zytram
Drug Type
Small Molecule
Chemical Formula
C16H25NO2
CAS Number
27203-92-5
Unique Ingredient Identifier
39J1LGJ30J
Background

Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of morphine.

Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as duloxetine and venlafaxine.

Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain.

Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators. Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain.

Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death. However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.

Indication

Tramadol is approved for the management of moderate to severe pain in adults.

Tramadol is also used off-label in the treatment of premature ejaculation.

Associated Conditions
Acute Pain, Premature Ejaculation, Severe Pain, Acute, moderate, severe Pain, Moderate Pain
Associated Therapies
-

A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain

Phase 3
Completed
Conditions
Low Back Pain
Interventions
First Posted Date
2008-04-21
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
802
Registration Number
NCT00662558
Locations
🇺🇸

Pfizer Investigational Site, Weber City, Virginia, United States

RCT on Ketorolac and Tramadol in Bone Fractures Pain of Child

Phase 4
Completed
Conditions
Fracture
Pain
Interventions
First Posted Date
2007-11-19
Last Posted Date
2017-08-24
Lead Sponsor
IRCCS Burlo Garofolo
Target Recruit Count
133
Registration Number
NCT00560443
Locations
🇮🇹

IRCCS Burlo Garofolo, Trieste, Italy

Comparison of Butorphanol and Tramadol Associated Patient-Controlled Analgesia (PCA) After Hysterectomy

Phase 4
Completed
Conditions
Postoperative Pain
Hysterectomy
Interventions
First Posted Date
2007-08-02
Last Posted Date
2009-03-31
Lead Sponsor
Nanjing Medical University
Target Recruit Count
841
Registration Number
NCT00510666
Locations
🇨🇳

Nanjing Maternal and Child Care Hospital, Nanjing, Jiangsu, China

The Discriminative Effects of Tramadol in Humans

Phase 1
Completed
Conditions
Stimulant Abuse
Stimulant Addiction
Opioid Abuse
Opioid Addiction
Interventions
First Posted Date
2007-07-11
Last Posted Date
2017-10-17
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
20
Registration Number
NCT00499746
Locations
🇺🇸

Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

Tramadol and Pain Sensitization

Phase 1
Completed
Conditions
Pain
First Posted Date
2007-06-15
Last Posted Date
2009-03-17
Lead Sponsor
University Hospital, Clermont-Ferrand
Target Recruit Count
12
Registration Number
NCT00487175
Locations
🇫🇷

CIC, Clermont-Ferrand, France

Norspan® Patches Versus Tramadol in Subjects With Chronic, Moderate to Severe Osteoarthritis Pain in the Hip Knee and/or Lumbar Spine

Phase 4
Completed
Conditions
Osteoarthritis
Pain
Interventions
First Posted Date
2007-01-25
Last Posted Date
2010-02-01
Lead Sponsor
Norpharma A/S
Target Recruit Count
120
Registration Number
NCT00426647
Locations
🇫🇮

Dr. Olavi Airaksinen, Oma Lääkäri Oy, Vuorikatu 20, Kuopio, Finland

Comparison of Tramadol vs Remifentanyl Patient Controlled Analgesia for Second Trimester Abortions

Not Applicable
Completed
Conditions
Abortion,Induced
First Posted Date
2006-08-08
Last Posted Date
2015-11-24
Lead Sponsor
Rabin Medical Center
Target Recruit Count
40
Registration Number
NCT00361686
Locations
🇮🇱

Rabin Medical Center, Petach Tiqvah, Israel

Comparison Between Tramadol Hcl and Other Analgesics in the Treatment of Renal Colic

Phase 4
Completed
Conditions
Renal Calculus
First Posted Date
2006-04-05
Last Posted Date
2009-02-17
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
100
Registration Number
NCT00310908
Locations
🇮🇱

Hadassah Medical Organization, Jerusalem, Israel

Assessment of Tramadol as a Treatment for Opioid Addiction

Phase 1
Completed
Conditions
Opioid-Related Disorders
Interventions
First Posted Date
2006-03-10
Last Posted Date
2015-04-17
Lead Sponsor
Johns Hopkins University
Target Recruit Count
9
Registration Number
NCT00301210
Locations
🇺🇸

Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

Tramadol to Reduce Opioid Withdrawal Symptoms

Phase 2
Completed
Conditions
Opioid-Related Disorders
First Posted Date
2005-09-02
Last Posted Date
2017-01-12
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
16
Registration Number
NCT00142896
Locations
🇺🇸

Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath